文献速递类风湿关节炎

静脉或皮下注射托珠单抗对类风湿关节炎患者报告生活质量结局的影响

Impact of tocilizumab administered intravenously or subcutaneously on patient-reported quality-of-life outcomes in patients with rheumatoid arthritis.
PubMed 文献 · RMD Open · 2018-06-17

基于OPTION、BREVACTA和SUMMACTA三项随机对照试验,评估静脉或皮下托珠单抗联合csDMARDs对类风湿关节炎患者报告结局的影响。与安慰剂相比,托珠单抗组更多患者达到≥MCID的改善和≥年龄性别匹配常模值的评分,静脉与皮下给药改善相似。

要点

  • OPTION中静脉托珠单抗组第16周50%-82%患者PRO改善≥MCID,安慰剂组31%-57%。
  • BREVACTA中皮下托珠单抗组第12周54%-73%患者改善≥MCID,安慰剂组42%-55%。
  • SUMMACTA中皮下组61%-84%、静脉组64%-84%患者第24周改善≥MCID。

核心结论

  • 静脉或皮下托珠单抗联合csDMARDs使更多患者报告有临床意义的改善及PRO评分≥常模值,静脉与皮下给药改善相似。

研究设计与样本

  • 研究基于OPTION(NCT00106548)、BREVACTA(NCT01232569)和SUMMACTA(NCT01194414)三项独立随机对照试验,评估静脉和/或皮下托珠单抗联合csDMARDs治疗类风湿关节炎的疗效与安全性。

主要发现

  • OPTION中静脉托珠单抗组第16周50%-82%患者PRO改善≥MCID,安慰剂组31%-57%;达到≥常模值者分别为16%-44% vs 5%-28%。
  • BREVACTA中皮下托珠单抗组第12周54%-73%患者改善≥MCID,安慰剂组42%-55%;达到≥常模值者分别为8%-34% vs 4%-25%。
  • SUMMACTA中皮下托珠单抗组第24周61%-84%患者改善≥MCID,静脉组64%-84%;达到≥常模值者分别为14%-41%和15%-24%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Randomised controlled trials (RCTs) have shown tocilizumab (TCZ) administered intravenously or subcutaneously with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) to be superior to csDMARDs alone for improving rheumatoid arthritis (RA) disease activity. This study evaluated the effect of TCZ-intravenous and TCZ-subcutaneous on patient-reported outcomes (PROs) in three RCT populations. METHODS: OPTION (NCT00106548), BREVACTA (NCT01232569) and SUMMACTA (NCT01194414) were independent RCTs evaluating the efficacy and safety of TCZ-intravenous and/or TCZ-subcutaneous with csDMARDs in patients with RA. PROs included patient global assessment, pain, Health Assessment Questionnaire-Disability Index, Functional Assessment of Chronic Illness Therapy-Fatigue and Short Form-36. Study outcomes included the proportions of patients reporting changes from baseline in PRO scores ≥ minimum clinically important differences (MCID) and scores ≥ age and gender-matched normative values. RESULTS: In OPTION, more patients who received TCZ-intravenous reported improvements in PROs ≥MCID (50%-82% vs 31%-57%) and scores ≥ normative values (16%-44% vs 5%-28%) at week 16 compared with placebo. Similarly, a greater proportion of patients in BREVACTA who received TCZ-subcutaneous reported improvements ≥ MCID (54%-73% vs 42%-55%) and scores ≥ normative values (8%-34% vs 4%-25%) at week 12 compared with placebo. In SUMMACTA, 61%-84% of patients who received TCZ-subcutaneous and 64%-84% of those who received TCZ-intravenous reported improvements ≥ MCID and 14%-41% and 15%-24%, respectively, scores ≥ normative values at week 24. CONCLUSIONS: TCZ-intravenous or TCZ-subcutaneous with csDMARDs resulted in more patients reporting clinically meaningful improvements and PRO scores ≥ normative values compared with placebo. These improvements were similar with TCZ-intravenous and TCZ-subcutaneous.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Strand V, Michalska M, Birchwood C, et al. Impact of tocilizumab administered intravenously or subcutaneously on patient-reported quality-of-life outcomes in patients with rheumatoid arthritis. RMD Open. 2018. PMID: 29955380. doi:10.1136/rmdopen-2017-000602

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。